Ed Silverman
Ed Silverman is a senior writer and Pharmalot columnist at STAT, where he has covered the pharmaceutical industry for over 25 years. Prior to joining STAT at its founding in 2015, he worked at The Wall Street Journal, The Star-Ledger of New Jersey, and New York Newsday. Ed has been recognized with prestigious awards such as the Gerald Loeb Award for business journalism commentary in 2018 and was a Pulitzer Prize finalist in explanatory journalism in 2016 for a series on prescription drug pricing. He holds an accounting degree from Binghamton University and a master's in journalism from New York University.
100%
The Daily's Verdict
This author is known for its high journalistic standards. The author strives to maintain neutrality and transparency in its reporting, and avoids conflicts of interest. The author has a reputation for accuracy and rarely gets contradicted on major discrepancies in its reporting.
Bias
100%
Examples:
No current examples available.
Conflicts of Interest
100%
Examples:
No current examples available.
Contradictions
100%
Examples:
No current examples available.
Deceptions
100%
Examples:
No current examples available.
Recent Articles
New HIV Prevention Drug Lenacapavir: Potential Price Drop to $40 per Year if Generics Allowed
Broke On: Tuesday, 23 July 2024New research suggests that the cost of producing Lenacapavir, a highly effective HIV prevention drug, could be as low as $40 per person a year if generic versions are allowed for manufacturing. This contrasts with its current price of over $40,000 per person a year in various countries. UNAIDS is urging Gilead Sciences to make the drug more accessible to people in developing countries and allow generic manufacturing through the UN-backed Medicines Patent Pool.